- Home
- NMRK vs TVTX Comparison
NMRK vs TVTX Comparison
Compare NMRK & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRK
- TVTX
- Stock Information
- Founded
- NMRK 1929
- TVTX 2008
- Country
- NMRK United States
- TVTX United States
- Employees
- NMRK N/A
- TVTX N/A
- Industry
- NMRK Real Estate
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- NMRK Finance
- TVTX Health Care
- Exchange
- NMRK Nasdaq
- TVTX Nasdaq
- Market Cap
- NMRK 2.0B
- TVTX 1.7B
- IPO Year
- NMRK 2017
- TVTX N/A
- Fundamental
- Price
- NMRK $11.22
- TVTX $20.02
- Analyst Decision
- NMRK Buy
- TVTX Strong Buy
- Analyst Count
- NMRK 4
- TVTX 14
- Target Price
- NMRK $15.67
- TVTX $33.31
- AVG Volume (30 Days)
- NMRK 1.1M
- TVTX 1.5M
- Earning Date
- NMRK 04-30-2025
- TVTX 05-01-2025
- Dividend Yield
- NMRK 1.06%
- TVTX N/A
- EPS Growth
- NMRK 81.01
- TVTX N/A
- EPS
- NMRK 0.38
- TVTX N/A
- Revenue
- NMRK $2,857,497,000.00
- TVTX $273,533,000.00
- Revenue This Year
- NMRK $11.92
- TVTX $68.31
- Revenue Next Year
- NMRK $9.07
- TVTX $55.65
- P/E Ratio
- NMRK $29.94
- TVTX N/A
- Revenue Growth
- NMRK 14.48
- TVTX 75.65
- 52 Week Low
- NMRK $9.64
- TVTX $6.01
- 52 Week High
- NMRK $16.10
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- NMRK 50.15
- TVTX 58.32
- Support Level
- NMRK $10.70
- TVTX $19.65
- Resistance Level
- NMRK $11.47
- TVTX $22.07
- Average True Range (ATR)
- NMRK 0.39
- TVTX 1.11
- MACD
- NMRK 0.13
- TVTX 0.31
- Stochastic Oscillator
- NMRK 80.62
- TVTX 69.58
About NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.